BTIG Maintains Buy Rating on Insulet (PODD)

Insulet Corporation (NASDAQ:PODD) is one of the

12 Oversold Blue Chip Stocks to Buy According to Analysts.

On April 13, 2026, BTIG lowered the price target on Insulet Corporation (NASDAQ:PODD) to $320 from $380 and maintained a Buy rating as part of a broader medical technology update. BTIG said it adjusted its model following CMS’ proposed FY27 inpatient prospective payment system rule, which includes commentary and decisions on new technology add-on payments.

On April 7, 2026, Citi downgraded Insulet Corporation (NASDAQ:PODD) to Neutral from Buy with a price target of $230, down from $338, ahead of the Q1 report. Citi cited increasing competition in the patch pump market, noting that new product launches in 2027 could limit share outperformance.

Meanwhile, on April 6, 2026, Evercore ISI lowered its price target on Insulet Corporation (NASDAQ:PODD) to $240 from $340 previously and maintained an Outperform rating as part of its Q1 preview for medical technology and life science tools.

Insulet Corporation (NASDAQ:PODD) develops and sells insulin delivery systems for diabetes patients.

While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.